Efektivnost Tocilizumaba nakon prevođenja sa intravenske na subkutanu formulaciju kod bolesnika sa reumatoidnim artritisom – iskustvo jednog centra
Sažetak
Kratak sažetak: Dobra kontrola reumatoidnog artritisa danas, podrazumeva odsustvo kliničke aktivnosti bolesti, usporavanje zglobne destrukcije i dobar kvalitet života obolelih. Uz danas dostupne terapijske modalitete, ovaj terapijski cilj dostižan je kod velikog broja bolesnika.
U ovoj studiji preseka ispitivali smo efektivnost IL-6 blokatora (Tociluzimaba) kod bolesnika sa RA u uslovima svakodnevne kliničke prakse. Takođe smo analizirali da li promena načina administracije leka (prevođenje sa intravenskog na subkutanu formulaciju leka) utiče na efektivnost leka (korišćenjem DAS 28 SE i CDAI indeksa) i kvalitet života bolesnika sa reumatoidnim artritisom (HAQ, Beckov indeks deprsivnosti, FACIT F skor i SF 36 upitnik).
Studija je obuhvatila 53 bolesnika sa reumatoidnim artritisom, na terapiji Tocilizumabom.
Nakon 6 meseci praćenja i primene subkutanog Tocilizumaba zaključili smo da način administarcije leka ne utiče na efektivost i sve ispitivane parametre procene kvaliteta života.
Reference
1. Zlatković-Švenda, M.I., Stojanović, R.M., B. Šipetić-Grujičić, S. et al. Prevalence of rheumatoid arthritis in Serbia. Rheumatol Int 34, 649–658 (2014).
https://doi.org/10.1007/s00296-013-2897-7
2. Smolen JS, Landewé RBM, Bijlsma JWJ, et alEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 updateAnnals of the Rheumatic Diseases 2020;79:685-699
http://dx.doi.org/10.1136/annrheumdis-2019-216655
3. Burmester GR, Rubbert-Roth A, Cantagrel A, et al. Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA); AnnRheum Dis 2016;75:68–74.
http://dx.doi.org/10.1136/annrheumdis-2015-207281
4. Darloy J, Segaud N, Salmon HJ et al. Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study; Rheumatol Ther (2019) 6:61–75
https://doi.org/10.1007/s40744-018-0138-y
5. Prevoo ML, van 't Hof MA, Kuper HH, et. al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995 Jan;38(1):44-8. PMID: 7818570
https://doi.org/10.1002/art.1780380107
6. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care, Best Practice & Research Clinical Rheumatology 2007; vol 21 (4): 663-675
https://doi.org/10.1016/j.berh.2007.02.004
7. Maska L, Anderson J, Michaud K. Measures of Functional Status and Quality of Life in Rheumatoid Arthritis, Arthritis Care & Research 2011; 63 (S11): 4-13.
https://doi.org/10.1002/acr.20620
8. Margaretten M., Julian L., Katz P, Yelin E. Depression in patients with rheumatoid arthritis: description, causes and mechanisms. International journal of clinical rheumatology 2011; 6 (6), 617–623.
https://doi.org/10.2217/IJR.11.6
9. Webster K, Cella D and Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation; Health and Quality of Life Outcomes 2003, 1:79-85.
https://doi.org/10.1186/1477-7525-1-79
10. Ware JE, Shelbourne CD. The MOS 36-item Short Form Health Survey (SF-36): conceptual framework and item selection. Med Care. 1992; 30 (6):473-83.
http://www.jstor.org/stable/3765916
11. Matcham F, Rayner L, Steer S, et al. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology 2013; 52:2136–48.
https://doi.org/10.1093/rheumatology/ket169
12. Geenen R, Dures E, A biopsychosocial network model of fatigue in rheumatoid arthritis: a systematic review, Rheumatology, 2019; 58 (5):v10-v21,
https://doi.org/10.1093/rheumatology/kez403
13. Fusama M, Nakahara H, Hamano Y. et al. Improvement of health status evaluated by Arthritis Impact Measurement Scale 2 (AIMS-2) and Short Form-36 (SF-36) in patients with rheumatoid arthritis treated with tocilizumab. Mod Rheumatol. 2013 Mar;23(2):276-83. doi: 10.1007/s10165-012-0674-1.
https://doi.org/10.3109/s10165-012-0674-1